Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy

 Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy

 A majority of currently used anticancer drugs belong to a group of chemical agents that damage DNA. The efficiency of the treatment is limited by effective DNA repair systems functioning in cancer cells. Many chemotherapeutic compounds cause strong systemic toxicity. Therefore, there is still a nee...

Full description

Bibliographic Details
Main Authors: Katarzyna Kluzek, Aneta Białkowska, Aleksandra Koczorowska, Małgorzata Z. Zdzienicka
Format: Article
Language:English
Published: Index Copernicus International S.A. 2012-06-01
Series:Postępy Higieny i Medycyny Doświadczalnej
Subjects:
BRCA1/2
homologous recombination
PARP inhibitors
anticancer therapy
geny BRCA1/2
rekombinacja homologiczna
inhibitory PARP
terapia przeciwnowotworowa
Online Access:http://journals.indexcopernicus.com/fulltxt.php?ICID=1000548

Internet

http://journals.indexcopernicus.com/fulltxt.php?ICID=1000548

Similar Items